To The Moon

Sign Up

AIM ImmunoTech Inc.(AIM)

POST1.290.000.00%19:10 EST
1.29-0.05-3.64%

Market data delayed 15 minutes

    • Winking Studios
      ·
      2024-11-21

      Video of Winking Studios’ AIM Listing

      https://www.youtube.com/watch?v=F9U2QrYcloU The London Stock Exchange welcomes Winking Studios Limited, the AAA Art Outsourcing and Game Development business listed on the Catalist board of the Singapore Exchange Securities Trading Limited, as it celebrates the company’s admission to the AIM Market of the London Stock Exchange. The Company has successfully raised £7.9 million, giving the company a market capitalisation on admission of approximately £66 million. It intends to use the proceeds raised to support expansion into Western markets and enhance the Group’s current operational capabilities. Founded in 2004 and headquartered in Singapore with nine offices across Asia, Winking Studios is led by its founder Johnny Jan and is ranked third in Asia and fourth in the world in terms of globa
      Video of Winking Studios’ AIM Listing
      Comment
      Report
      Winking Studios
      ·
      2024-11-16

      Winking Studios rises on AIM debut in London on 14 Nov 2024

      Winking Studios Ltd saw its share price rise on Thursday, as it started trading on London's junior market. The Singapore-based video-game services firm backed by Taiwan's Acer Inc announced the admission of its shares to AIM two weeks after revealing its plans for an initial public offering. Its shares were trading up 12% at 16.75 pence from its IPO price of 15p on Thursday morning in London. Winking already was listed in Singapore, where it closed flat at SDG0.29, or 17.00p, on Thursday. This follows a share placing on Monday that raised GBP7.9 million at 15p per share, giving Winking a GBP66.1 million opening market capitalisation. Winking issued 52.7 million new shares, with Acer's 62.6% holding prior to the IPO rising to 64.2% as subsidiary Acer Gaming Inc bought 40 million of the new
      Winking Studios rises on AIM debut in London on 14 Nov 2024
      Comment
      Report
      Grafa
      ·
      2024-04-18

      Celsius Resources (ASX:CLA) gets £117,317 boost from Silvercorp Metals after AIM placement

      Celsius Resources secured a £117,317 ($226,777) investment from major shareholder Silvercorp Metals following a recent AIM placement that raised £922,000 ($1.8 million). Silvercorp's investment is part of its agreed participation right, allowing it to subscribe to 19,552,752 new shares at £0.006 each, with accompanying warrants. The funds will support development works at various projects and bolster general working capital. Claim Now
      Celsius Resources (ASX:CLA) gets £117,317 boost from Silvercorp Metals after AIM placement
      Comment
      Report
      Grafa
      ·
      2024-04-15

      Celsius Resources (ASX:CLA) completes £922,000 placement on AIM

      Celsius Resources completed a £922,000 ($1.8 million) placement on the AIM, issuing 153,666,663 new ordinary shares and warrants exercisable at 0.9 pence each until Dec. 31, 2026. Priced at 0.6 pence each, the placement targeted institutional investors. Funds raised will finance early development, exploration, and general working capital for projects like MCB Copper-Gold and Sagay Copper-Gold. No shareholder approval was required. Post-placement, total ordinary shares will increase to 2,408,359,991. Trading of the shares on AIM is expected to start on April 18. Claim Now
      Celsius Resources (ASX:CLA) completes £922,000 placement on AIM
      Comment
      Report
      Smartkarma
      ·
      2023-10-22

      China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine

      ⬇ $AIM Vaccine(06660)$ - Weight loss and Alzheimer's disease (AD) would generate different investment returns.We're conservative about the outlook of GLP-1 gene therapy.We consider AIM Vaccine risky and recommend staying away Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-oct-20-investment-returns-on-weight-loss-ad-glp-1-gene-therapy-aim-vaccine?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On AIM Vaccine (06660):- https://www.smartkarma.com/entities/aim-vaccine-co-ltd?utm_source=tiger_community
      China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine
      Comment
      Report
      NAI500
      ·
      2023-05-23

      Stock Picking Pool: The Best Financial Stocks for May 2023

      In the past 12 months to May 11, 2023, although the financial sector is still in decline overall, the stocks of $Waterdrop Inc.(WDH)$ $UniCredito Spa(UNCFF)$ and $First Citizens BancShares Inc (DE)(FCNCP)$ . Top the tracking returns reached 168%, 127% and 96% respectively.The $Financial Select Sector SPDR Fund(XLF)$ which represents financial stocks, fell 12% between March 8 and March 17 alone, as news of the collapse of $Signature Bank(SBNY)$ and $SVB Financial Group(SIVBQ)$ in March sparked an earthquake in the financial sector.The i
      Stock Picking Pool: The Best Financial Stocks for May 2023
      # 💰Stocks to watch today?(9 Jan）
      TOPisjanjan: Great ariticle, would you like to share it?
      17
      Report
      Smartkarma
      ·
      2023-04-02

      China Healthcare Weekly (Mar.31) - 8th National VBP Result, Chinese Patent Medicine VBP, AIM Vaccine

      ⬇ $AIM Vaccine(06660)$ - The 8th national VBP released results.The impact of VBP on companies is decreasing. Chinese patent medicine VBP is coming, but some companies can cope well.AIM doesn’t have long-term investment value. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-mar-31-8th-national-vbp-result-chinese-patent-medicine-vbp-aim-vaccine?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On AIM Vaccine (06660):- https://www.smartkarma.com/entities/aim-vaccine-co-ltd?utm_source=tiger_community
      China Healthcare Weekly (Mar.31) - 8th National VBP Result, Chinese Patent Medicine VBP, AIM Vaccine
      6
      Report
      SlowIncome
      ·
      2022-04-27
      (27/04)Today's pre-market BOOMs:$Cosmos Holdings Inc.(COSM)$$Vivakor, Inc.(VIVK)$$Acutus Medical(AFIB)$$Caladrius Biosciences(CLBS)$$AIM ImmunoTech...
      # 💰Stocks to watch today?(9 Jan）
      Comment
      Report

    • Company Profile

      Company Name
      AIM ImmunoTech Inc.
      Market
      AMEX
      Establishment Date
      - -
      Employees
      - -
      Office Location
      - -
      Website
      http://www.aimimmuno.com
      Zip Code
      - -
      Phone
      - -
      Fax
      - -
      Introduction
      AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
    • 1D
    • 5D
    • Day
    • Week
    • Month

    Loading ...

    High
    1.40
    Open
    1.40
    Volume%
    2.33
    Low
    1.26
    Close
    1.34
    T/O Rate
    5.91%
     
     
     
     

    Most Discussed